Goldman Sachs Tempers Expectations on Tempus AI Amid Regulatory Milestones

Goldman Sachs has initiated coverage of Tempus AI Inc (no ticker mentioned) with a Neutral rating and a price target of $75.00, despite the stock currently trading at $77.84.

The firm notes that Tempus operates two product lines: Diagnostics and Data, which are designed to build on each other over time, creating a synergistic relationship between their offerings for both patients and pharma partners.

Goldman Sachs sees the Diagnostics business poised to benefit from multiple pricing tailwinds, including the recent FDA approval of the solid tumor xT companion diagnostic assay. This allows Tempus to raise the reimbursement rate for the test, which management expects will yield a $200 average selling price uplift and $85 million in annualized revenue starting in 2027.

The firm states that regulatory milestones could unlock up to $400 million in incremental revenue by 2028, significantly expanding margins without requiring heavy commercial reinvestment. Tempus already maintains a strong gross profit margin of 64% on its current revenue base of $1.43 billion, which grew 50% over the last twelve months.

However, Goldman Sachs identifies potential near-term risks within the Data and Applications segment, including high customer concentration, with the top five customers representing 59% of revenue. Emerging data monetization efforts from diagnostic peers and lack of exclusive electronic health record data rights create uncertainty on long-term market share dynamics.